The Epithelial Discoidin Domain Containing Receptor 1 pipeline drugs market research report outlays comprehensive information on the Epithelial Discoidin Domain Containing Receptor 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Epithelial Discoidin Domain Containing Receptor 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Oncology, Respiratory, Genito Urinary System, and Central Nervous System which include the indications Solid Tumor, Liver Cancer, Pulmonary Fibrosis, Kidney Fibrosis, Chronic Kidney Disease (Chronic Renal Failure), Alzheimer’s Disease, and Parkinson’s Disease. It also reviews key players involved in Epithelial Discoidin Domain Containing Receptor 1 targeted therapeutics development with respective active and dormant or discontinued products.

The Epithelial Discoidin Domain Containing Receptor 1 pipeline targets constitutes close to 12 molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 4, 2, 2, and 1 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 2, and 1 molecule.

Epithelial Discoidin Domain Containing Receptor 1 overview

Epithelial discoidin domain containing receptor 1 (DDR1) is a type of receptor protein that belongs to the discoidin domain receptor family. DDR1 is a receptor tyrosine kinase, it is involved in signaling pathways that regulate various cellular processes. DDR1 is primarily expressed in epithelial cells, which are the cells that form the linings and coverings of various tissues in the body, including the skin, lungs, and digestive tract.

For a complete picture of Epithelial Discoidin Domain Containing Receptor 1’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.